医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions
pros Therapeutics, Inc., a drug discovery and development company focused on tissue-targeted Toll-Like Receptor 7 (TLR7) agonists for the treatment of cancer and infectious diseases, announced that its Investigational New Drug (IND) application for a Phase 1 dose escalation trial of APR003, the company’s first-in-class orally-administered gastrointestinal- and liver-targeted TLR7 agonist development candidate, was cleared by the FDA. The Phase 1 trial aims to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and initial anti-tumor activity of APR003 in patients with advanced unresectable CRC with malignant liver lesions. The trial will be conducted at multiple sites in the United States, and the company intends to report top-line results upon completion.… 続きを読む
2020年09月09日 PM07:00
2020年09月09日
Taiwan Innotech Expo (TIE) Showcases Strong Ecosystems in the Post-Pandemic World
ver 1,000 innovative technologies will lead Taiwan into a smart future! The annual Taiwan Innotech Expo, which brings together industry, government and academia, will be launched at Taipei World Trade Center Hall 1 on September 24, 2020. The Expo exhibitions will revolve around “Resilient Taiwan for a Smart Future” under the themes of “Future Tech”, “Innovation Pilot” and “Sustainability”. By creating a diversified trading platform, combining local innovation dynamics and regional advantages, and connecting ASEAN countries with Europe, the US, and Japan, Taiwan will become a global IP hub for technology R&D and trading to spread its innovation around the world and promote its “smart value.” Embrace the era of innovation and intelligence with the help of big data This year, the “Innovation Pilot” theme will demonstrate more than 100 innovative technologies and visualize the transition to the hyper digitization era. This theme consists of four topics: Hyper Automation, IoT, Multi Experience, and New Health. Each of the topics will be presented in different highlights such as the Defense Tech, the Disaster Management Solutions, Future Mobility, and Epidemic Prevention Tech.… 続きを読む
2020年09月09日
Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market
r. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of over-the-counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. market.… 続きを読む
2020年09月09日
随着越来越多的客户和合作伙伴使用Denodo冠状病毒数据门户计划来对抗和最小化COVID-19的影响,其采纳率在不断提高
数据虚拟化的领导者Denodo今天宣布,冠状病毒数据门户 (CDP)的采用率日益增加。这项开放式协作计划利用数据虚拟化来统一来自多个来源和国家、最初采用不同格式的重要数据集。Denodo最初是在大流行早期的3月份进行开发的,它综合并统一了与COVID-19相关的情报,并将其提供给数据使用者,例如数据科学家、分析人员和研究人员,他们利用这些信息来寻找解决该全球性疾病的方法。如需了解更多信息或参与其中,请访问https://www.coronavirusdataportal.com。… 続きを読む
2020年09月09日
GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise
tomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross Corporation, to discover and develop novel hemophilia therapies. GC Pharma is a pioneer in vaccines and protein therapeutics and has long been dedicated to research and development of hemophilia treatments, currently developing its non-factor therapy for hemophilia A. GC Pharma’s partnership with Atomwise will enable the expansion of its hemophilia business and launch multiple discovery programs to develop a small molecule therapy for hemophilia and other indications.… 続きを読む